Evidence map›Paper›PMID 30360466›Full record

ReviewMolecules (Basel, Switzerland)2018

Current Therapies Focused on High-Density Lipoproteins Associated with Cardiovascular Disease.

Diego Estrada-Luna, María Araceli Ortiz-Rodriguez, Lizett Medina-Briseño, Elizabeth Carreón-Torres, Jeannett Alejandra Izquierdo-Vega, Ashutosh Sharma, Juan Carlos Cancino-Díaz, Oscar Pérez-Méndez, Helen Belefant-Miller, Gabriel Betanzos-Cabrera

Open access · goldFull text readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 50 citations in OpenAlex.

  1. Trial
  2. Review
  3. From lipid overload to autophagy collapse: how lipid dysregulation drives chronic inflammation and metabolic disease.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Styrylpyrones fromAntioxidants (Basel, Switzerland) · 2022
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Post-translational modifications of S1PR1 and endothelial barrier regulation.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2020
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 2 countries.

Diego Estrada-LunaInstituto Nacional de Cardiología "Ignacio Chávez" Juan Badiano No. 1, Belisario Domínguez Sección 16, 14080 Tlalpan, Mexico City, Mexico. diego.estrada.luna@gmail.com.
María Araceli Ortiz-RodriguezFacultad de Nutrición, Universidad Autónoma del Estado de Morelos, UAEM, Calle Río Iztaccihuatl S/N, Vista Hermosa, 62350 Cuernavaca, Morelos, Mexico. araceli.ortiz@gmail.com.ORCID 0000-0003-0847-0261
Lizett Medina-BriseñoUniversidad de la Sierra Sur, UNSIS, Miahuatlán de Porfirio Díaz, 70800 Oaxaca, Mexico. lizmedinab@gmail.com.
Elizabeth Carreón-TorresInstituto Nacional de Cardiología "Ignacio Chávez" Juan Badiano No. 1, Belisario Domínguez Sección 16, 14080 Tlalpan, Mexico City, Mexico. qfbelizabethcm@yahoo.es.ORCID 0000-0003-3600-249X
Jeannett Alejandra Izquierdo-VegaÁrea Académica de Medicina, Instituto de Ciencias de la Salud, Universidad Autónoma del Estado de Hidalgo, Carretera Actopan-Tilcuautla, Ex-Hacienda La Concepción S/N, San Agustín Tlaxiaca, 42160 Hidalgo, Mexico. jizquierdovega@gmail.com.
Ashutosh SharmaTecnologico de Monterrey, School of Engineering and Sciences, Campus Queretaro, Epigmenio Gonzalez 500, 76130 Queretaro, Mexico. asharma@itesm.mx.
Juan Carlos Cancino-DíazDepartamento de Microbiología, Escuela Nacional de Ciencias Biológicas del Instituto Politécnico Nacional, 11340 Ciudad de México, Mexico. jccancinodiaz@hotmail.com.
Oscar Pérez-MéndezInstituto Nacional de Cardiología "Ignacio Chávez" Juan Badiano No. 1, Belisario Domínguez Sección 16, 14080 Tlalpan, Mexico City, Mexico. opmendez@yahoo.com.
Helen Belefant-MillerDale Bumpers National Rice Research Center, Stuttgart, AR 72160, USA. drhelenmiller@gmail.com.ORCID 0000-0002-9847-8824
Gabriel Betanzos-CabreraÁrea Académica de Medicina, Instituto de Ciencias de la Salud, Universidad Autónoma del Estado de Hidalgo, Carretera Actopan-Tilcuautla, Ex-Hacienda La Concepción S/N, San Agustín Tlaxiaca, 42160 Hidalgo, Mexico. gbetanzo@uaeh.edu.mx.ORCID 0000-0003-2027-6904
Instituto Nacional de Cardiología · MXUniversidad Autónoma del Estado de Hidalgo · MXDale Bumpers National Rice Research Center · USInstituto Politécnico Nacional · MXTecnológico de Monterrey · MXUniversidad Autónoma del Estado de Morelos · MXUniversidad de la Sierra · MX

Funding

Consejo Nacional de Ciencia y Tecnología PDCPN2013-01 and SALUD-2010-01-142035
6 · The paper itself

Abstract

High-density lipoproteins (HDL) comprise a heterogeneous family of lipoprotein particles divided into subclasses that are determined by density, size and surface charge as well as protein composition. Epidemiological studies have suggested an inverse correlation between High-density lipoprotein-cholesterol (HDL-C) levels and the risk of cardiovascular diseases and atherosclerosis. HDLs promote reverse cholesterol transport (RCT) and have several atheroprotective functions such as anti-inflammation, anti-thrombosis, and anti-oxidation. HDLs are considered to be atheroprotective because they are associated in serum with paraoxonases (PONs) which protect HDL from oxidation. Polyphenol consumption reduces the risk of chronic diseases in humans. Polyphenols increase the binding of HDL to PON1, increasing the catalytic activity of PON1. This review summarizes the evidence currently available regarding pharmacological and alternative treatments aimed at improving the functionality of HDL-C. Information on the effectiveness of the treatments has contributed to the understanding of the molecular mechanisms that regulate plasma levels of HDL-C, thereby promoting the development of more effective treatment of cardiovascular diseases. For that purpose, Scopus and Medline databases were searched to identify the publications investigating the impact of current therapies focused on high-density lipoproteins.

Indexed as

AnimalsBiomarkersCardiovascular DiseasesCholesterol, HDLEndothelial CellsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsLipid MetabolismLipoproteinsLipoproteins, HDLOxidation-ReductionBiomarkersCholesterol, HDLHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsLipoproteinsLipoproteins, HDLHDL-Clipoproteinsparaoxonasepolyphenols

Identifiers

PMID30360466
PMCPMC6278283
OpenAlexW2897197406

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.